In part 2 of this panel discussion, the panelists discuss the divide between investments being made by Pharma and CROs in new bioanalytical techniques and technologies.

Discussions include:

Investments made by Pharma and CROs for new constructs Is there a real divide between CRO and Pharma? If so, why is this occurring? What are the gaps? What are the solutions?